[{"address1": "704 Quince Orchard Road", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "617 923 1400", "website": "https://www.cartesiantherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 37, "auditRisk": 10, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 22.89, "open": 22.94, "dayLow": 22.095, "dayHigh": 24.23, "regularMarketPreviousClose": 22.89, "regularMarketOpen": 22.94, "regularMarketDayLow": 22.095, "regularMarketDayHigh": 24.23, "forwardPE": -4.7204967, "volume": 135182, "regularMarketVolume": 135182, "averageVolume": 96813, "averageVolume10days": 103620, "averageDailyVolume10Day": 103620, "bid": 22.35, "ask": 23.44, "bidSize": 100, "askSize": 100, "marketCap": 405751072, "fiftyTwoWeekLow": 11.665, "fiftyTwoWeekHigh": 42.6, "priceToSalesTrailing12Months": 15.6624365, "fiftyDayAverage": 25.1405, "twoHundredDayAverage": 25.752174, "currency": "USD", "enterpriseValue": 312789024, "floatShares": 3585371, "sharesOutstanding": 17796100, "sharesShort": 948355, "sharesShortPriorMonth": 638538, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0533, "heldPercentInsiders": 0.60727, "heldPercentInstitutions": 0.118360005, "shortRatio": 9.91, "shortPercentOfFloat": 0.47, "impliedSharesOutstanding": 17796100, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -292420992, "forwardEps": -4.83, "lastSplitFactor": "1:30", "lastSplitDate": 1712275200, "enterpriseToRevenue": 12.074, "enterpriseToEbitda": -4.582, "52WeekChange": -0.2962963, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RNAC", "underlyingSymbol": "RNAC", "shortName": "Cartesian Therapeutics, Inc.", "longName": "Cartesian Therapeutics, Inc.", "firstTradeDateEpochUtc": 1466602200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3aa1e7f5-c6ee-368f-aab4-bd0bea306209", "messageBoardId": "finmb_371375105", "gmtOffSetMilliseconds": -14400000, "currentPrice": 22.8, "targetHighPrice": 54.0, "targetLowPrice": 38.0, "targetMeanPrice": 43.83, "targetMedianPrice": 41.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 103418000, "totalCashPerShare": 5.811, "ebitda": -68263000, "totalDebt": 10457000, "quickRatio": 2.941, "currentRatio": 3.031, "totalRevenue": 25906000, "revenuePerShare": 4.938, "operatingCashflow": -58313000, "revenueGrowth": -0.017, "grossMargins": -1.18301, "ebitdaMargins": -2.6350298, "operatingMargins": -2.23425, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]